Physician profile
Stacey Olney
NPI 1275699365
$2,475.66
in general payments reported to CMS, 2019-2025
36 companies · $401 in 2025
The $401 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $106 · 2021: $172 · 2022: $568 · 2023: $637 · 2024: $187 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139 · Education: $85.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,139.25 |
| Education | $85.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $518.07 | 2019-2025 | |
| Astellas Pharma US INC | $336.04 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $180.59 | 2021-2025 | |
| Pfizer INC. | $145.95 | 2019-2025 | |
| Exeltis, USA INC. | $122.75 | 2023-2025 | Slynd |
| Channel Medsystems, INC. | $76.15 | 2022 | |
| Therapeuticsmd, INC. | $72.05 | 2019-2022 | |
| Daiichi Sankyo INC. | $63.95 | 2019-2022 | |
| Alydia Health | $61.26 | 2021 | |
| Avion Pharmaceuticals | $60.85 | 2022-2023 | Balcoltra |
| Applied Medical Resources Corporation | $58.19 | 2023 | |
| Sumitomo Pharma America, INC. | $57.70 | 2023-2025 | Myfembree |
| Organon LLC | $56.94 | 2022-2024 | Nexplanon |
| Allergan, INC. | $53.93 | 2019-2020 | |
| Baxter Healthcare | $48.67 | 2022-2025 | Perclot |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $48.67 | 2022 | |
| Duchesnay USA Incorporated | $47.97 | 2019 | |
| Biogen, INC. | $39.80 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $38.24 | 2023-2025 | |
| Novo Nordisk INC | $35.49 | 2019 | |
| Roche Diagnostics Corporation | $35.26 | 2019 | |
| Dexcom, INC. | $32.93 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $30.49 | 2025 | |
| Exact Sciences Corporation | $29.66 | 2024 | Cologuard Collection Kit |
| Minerva Surgical, INC | $27.80 | 2020 | |
| Merck Sharp & Dohme LLC | $26.67 | 2020-2023 | Gardasil 9 |
| Lupin INC. | $24.49 | 2019 | |
| Millicent US INC | $23.44 | 2025 | Intrarosa, Femring |
| Agile Therapeutics, INC. | $23.24 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.85 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.63 | 2021 | |
| Medtronic, INC. | $18.10 | 2022 | |
| Hologic Sales and Service, LLC | $16.34 | 2023 | Aptima, Thinprep 2000 Processor |
| Coopersurgical, INC. | $13.89 | 2023 | Paragard T 380a |
| Molnlycke Health Care US, LLC | $11.61 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Olney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.